Synergistic effects of cisplatin chemotherapy and gold nanorod-mediated hyperthermia on ovarian cancer cells and tumors

Nanomedicine

Volumn 9, Issue 13, 2014, Pages 1939-1955

  Mehtala, Jonathan G ^a   Torregrosa Allen, Sandra ^a   Elzey, Bennett D ^b   Jeon, Mansik ^c   Kim, Chulhong ^c   Wei, Alexander ^a  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c Pohang University of Science and Technology (POSTECH)   (South Korea)

Author keywords

apoptosis; cisplatin; gold nanorods; hyperthermia; ovarian cancer; synergistic effects

Indexed keywords

CISPLATIN; GOLD NANOPARTICLE; GOLD NANOROD; MACROGOL; NANOROD; UNCLASSIFIED DRUG; GOLD; NANOTUBE;

ABSORPTION SPECTROSCOPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL VIABILITY ASSAY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HEATING; HUMAN; HUMAN CELL; HYPERTHERMIA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOMEDICINE; NONHUMAN; OVARY CANCER; PILOT STUDY; SYNTHESIS; TREATMENT OUTCOME; TUMOR VOLUME; APOPTOSIS; DRUG EFFECTS; HYPERTHERMIC THERAPY; MULTIMODALITY CANCER THERAPY; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; COMBINED MODALITY THERAPY; DRUG SYNERGISM; FEMALE; GOLD; HUMANS; HYPERTHERMIA, INDUCED; NANOTUBES; OVARIAN NEOPLASMS;

EID: 84908299045     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.209     Document Type: Article

References (70)

1. Wei A, Thomas M, Mehtala JG et al. Gold nanoparticles as multifunctional materials in cancer nanotechnology. In: Biomaterials for Cancer Therapeutics. Park K (Ed.). Woodhead Publishing, Cambridge, UK, 349-386 (2013).
2. Thakor AS, Jokerst JV, Zavaleta CL et al Gold Nanoparticles: A Revival in Precious Metal Administration to Patients. Nano Lett. 11(10), 4029-4036 (2011).
3. Dreaden EC, Alkilany AM, Huang X et al. The golden age: Gold nanoparticles for biomedicine. Chem. Soc. Rev. 41(7), 2740-2779 (2012).
4. Guo R, Zhang L, Qian H et al. Multifunctional nanocarriers for cell imaging, drug delivery, and near-IR photothermal therapy. Langmuir 26(8), 5428-5434 (2010).
5. Tong L, Wei Q, Wei A et al. Gold nanorods as contrast agents for biological imaging: Surface conjugation, two-photon luminescence, and photothermal effects. Photochem. Photobiol. 85(1), 21-32 (2009).
6. Huff TB, Tong L, Zhao Y et al. Hyperthermic effects of gold nanorods on tumor cells. Nanomedicine 2(1), 125-132 (2007).
7. Tong L, Zhao Y, Huff TB et al. Gold nanorods mediate tumor cell death by compromising membrane integrity. Adv. Mater. 19(20), 3136-3141 (2007).
8. Tong L, Cheng J-X. Gold nanorod-mediated photothermolysis induces apoptosis of macrophages via damage of mitochondria. Nanomedicine 4(3), 265-276 (2009).
9. Wang CG, Chen J, Talavage T et al. Gold nanorod/Fe3O4 nanoparticle 'nano-pearl-necklaces' for simultaneous targeting, dual-mode imaging, and photothermal ablation of cancer cells. Angew. Chem. Int. Ed. 48(15), 2759-2763 (2009).
10. Yi DK, Sun I-C, Ryu JH et al. Matrix metalloproteinase sensitive gold nanorod for simultaneous bioimaging and photothermal therapy of cancer. Bioconjugate Chem. 21(12), 2173-2177 (2010).
11. Shen S, Tang H, Zhang X et al. Targeting mesoporous silica-encapsulated gold nanorods for chemo-photothermal therapy with near-infrared radiation. Biomaterials 34(12), 3150-3158 (2013).
12. Ratto F, Matteini P, Rossi F et al. Photothermal effects in connective tissues mediated by laser-Activated gold nanorods. Nanomed. Nanotechnol. Biol. Med. 5(2), 143-151 (2009).
13. Dickerson EB, Dreaden EC, Huang X et al. Gold nanorod assisted near-infrared plasmonic photothermal therapy (PPTT) of squamous cell carcinoma in mice. Cancer Lett. 269(1), 57-66 (2008).
14. Von Maltzahn G, Park J-H, Agrawal A et al. Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. Cancer Res. 69(9), 3892-3900 (2009).
15. Goodrich GP, Bao LL, Gill-Sharp K et al. Photothermal therapy in a murine colon cancer model using near-infrared absorbing gold nanorods. J. Biomed. Opt. 15(1), 018001 (2010).
16. Niidome T, Akiyama Y, Yamagata M et al. Poly(ethylene glycol)-modified gold nanorods as a photothermal nanodevice for hyperthermia. J. Biomater. Sci. Polym. Ed. 20(9), 1203-1215 (2009).
17. Shiotani A, Akiyama Y, Kawano T et al. Active accumulation of gold nanorods in tumor in response to near-infrared laser irradiation. Bioconjugate Chem. 21(11), 2049-2054 (2010).
18. Choi WI, Kim J-Y, Kang C et al. Tumor regression in vivo by photothermal therapy based on gold-nanorod-loaded, functional nanocarriers. ACS Nano 5(3), 1995-2003 (2011).
19. National Library of Medicine, MD, US Pilot Study of AuroLaseTM Therapy in Refractory and/or Recurrent Tumors of the Head and Neck (2000). http://clinicaltrials.gov/show/NCT00848042
20. Zhang XD, Wu D, Shen X et al. Size-dependent in vivo toxicity of PEG-coated gold nanoparticles. Int. J. Nanomed. 6, 2071-2081 (2011).
21. Cho WS, Cho M, Jeong J et al. Acute toxicity and pharmacokinetics of 13 nm-sized PEG-coated gold nanoparticles. Toxicol. Appl. Pharmacol. 236(1), 16-24 (2009).
22. Balasubramanian SK, Jittiwat J, Manikandan J et al. Biodistribution of gold nanoparticles and gene expression changes in the liver and spleen after intravenous administration in rats. Biomaterials 31(8), 2034-2042 (2010).
23. Kapp DS, Hahn GM, Carlson RW. Principles of hyperthermia. In: Holland-Frei Cancer Medicine (5th Edition). BC Decker, ON, USA, Chapter 35 (2000).
24. Gas P. Essential facts on the history of hyperthermia and their connections with electromedicine. Przeglad Elektrotechniczny 87(12b), 37-40 (2011).
25. Hahn GM, Braun J, Har-Kedar I. Thermochemotherapy: Synergism between hyperthermia (42-43 degrees) and adriamycin (or bleomycin) in mammalian cell inactivation. Proc. Natl. Acad. Sci. USA 72(3), 937-940 (1975).
26. Yatvin MB, Clifton KH, Dennis WH. Hyperthermia and local anesthetics: Potentiation of survival of tumor-bearing mice. Science 205(4402), 195-196 (1979).
27. Coffey DS, Getzenberg RH, DeWeese TL. Hyperthermic biology and cancer therapies: A hypothesis for the 'Lance Armstrong effect'. JAMA 296(4), 445-448 (2006).
28. Michalakis J, Georgatos SD, Bree E et al. Short-Term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long-Term inhibition of cell proliferation and cell death in vitro. Ann. Surg. Oncol. 14(3), 1220-1228 (2007).
29. Hauck TS, Jennings TL, Yatsenko T et al. Enhancing the toxicity of cancer chemotherapeutics with gold nanorod hyperthermia. Adv. Mater. 20(20), 3832-3838 (2008).
30. Lee S-M, Park H, Choi J-W et al. Multifunctional nanoparticles for targeted chemophotothermal treatment of cancer cells. Angew. Chem. Int. Ed. 50(33), 7581-7586 (2011).
31. Zhang W, Guo Z, Huang D et al. Synergistic effect of chemo-photothermal therapy using PEGylated graphene oxide. Biomaterials 32(33), 8555-8561 (2011).
32. Jang B, Park J-Y, Tung C-H et al. Gold nanorod-photosensitizer complex for near-infrared fluorescence imaging and photodynamic/photothermal therapy in vivo. ACS Nano 5(2), 1086-1094 (2011).
33. Kelland LR, Murrer BA, Abel G et al. Ammine/amine platinum(IV) dicarboxylates: A novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 52(4), 822-828 (1992).
34. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7(8), 573-584 (2007).
35. Ana-Maria F, Büsselberg D: Cisplatin as an anti-Tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers 3, 1351-1371 (2011).
36. Florence AT. 'Targeting' nanoparticles: The constraints of physical laws and physical barriers. J. Control. Release 164(2), 115-124 (2012).
37. Denison TA, Bae YH. Tumor heterogeneity and its implication for drug delivery. J. Control Release 164(2), 187-191 (2012).
38. Sau TK, Murphy CJ. Seeded high yield synthesis of short Au nanorods in aqueous solution. Langmuir 20(15), 6414-6420 (2004).
39. Zweifel DA, Wei A. Sulfide-Arrested growth of gold nanorods. Chem. Mater. 17(16), 4256-4261 (2005).
40. Alley MC, Scudiero DA, Monks A et al. Feasibility of drug screening with panels of human tumor cell lines using a Mmicroculture tetrazolium assay. Cancer Res. 48(3), 589-601 (1988).
41. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 119(2), 203-210 (1989).
42. Kim C, Jeon M, Wang LV. Nonionizing photoacoustic cystography in vivo. Opt. Lett. 36(18), 3599-3601 (2011).
43. Mehtala JG, Max JP, Zhao S et al. Citrate-stabilized gold nanorods. (Submitted) (2014).
44. Orendorff CJ, Murphy CJ. Quantitation of metal content in the silver-Assisted growth of gold nanorods. J. Phys. Chem. B 110(9), 3990-3994 (2006).
45. Huff TB, Hansen MH, Zhao Y et al. Controlling the cellular uptake of gold nanorods. Langmuir 23(4), 1596-1599 (2007).
46. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discovery 4(4), 307-320 (2005).
47. Roti Roti JL, Kampinga HH, Malyapa RS et al. Nuclear matrix as a target for hyperthermia killing of cancer cells. Cell Stress Chaperones 3(4), 245-255 (1998).
48. Los G, Sminia P, Wondergem J et al. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur. J. Cancer 27(4), 472-177 (1991).
49. Los G, Vugt MJH, Pinedo HM. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br. J. Cancer 69, 235-241 (1994).
50. Ohno S, Siddik ZH, Baba H et al. Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats. Cancer Res. 51, 2994-3000 (1991).
51. Fuertes MA, Alonso C, Perez JM. Biochemical modulation of cisplatin mechanisms of action: Enhancement of antitumor activity and circumvention of drug resistance. Chem. Rev. 103(3), 645-662 (2002).
52. Tulub AA, Stefanov VE. Cisplatin stops tubulin assembly into microtubules. A new insight into the mechanism of antitumor activity of platinum complexes. Int. J. Biol. Macromol. 28(3), 191-198 (2001).
53. Hostetter AA, Osborn MF, DeRose VJ. RNA-Pt adducts following cisplatin treatment of Saccharomyces cerevisiae. ACS Chem. Biol. 7(1), 218-225 (2012).
54. Damsma GE, Alt A, Brueckner F et al. Mechanism of transcriptional stalling at cisplatin damaged DNA. Nat. Struct. Mol. Biol. 14(12), 1127-1133 (2007).
55. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 481(7381), 287-294 (2012).
56. Meyn RE, Corry PM, Fletcher SE et al. Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum(II). Cancer Res. 40(4), 1136-1139 (1980).
57. Powell SN, Kachnic LA. Homologous recombination research is heating up and ready for therapy. Proc. Natl. Acad. Sci. USA 108(24), 9731-9732 (2011).
58. Lepock JR. Involvement of membranes in cellular responses to hyperthermia. Radiat. Res. 92(3), 433-438 (1982).
59. Gabano E, Colangelo D, Ghezzi AE et al. The influence of temperature on antiproliferative effects, cellular uptake and DNA platination of the clinically employed Pt(II)-drugs. J. Inorg. Biochem. 102(4), 629-635 (2008).
60. Lepock JR, Frey HE, Heynen ML et al. The nuclear matrix is a thermolabile cellular structure. Cell Stress Chaperones 6(2), 136-147 (2001).
61. Krawczyk PM, Eppink B, Essers J et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc. Natl. Acad. Sci. USA 108(24), 9851-9856 (2011).
62. Verwaal VJ, van Ruth S, de Bree E et al. randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J. Clin. Oncol. 21(20), 3737-3743 (2003).
63. Levi-Polyachenko NH, Stewart JH. Clinical relevance of nanoparticle induced hyperthermia for drug delivery and treatment of abdominal cancers. Open Nanomed. J. 3, 24-37 (2011).
64. Saito K, Yoshimura H, Ito K et al. Clinical trials of interstitial microwave hyperthermia by use of coaxial-slot antenna with two slots. IEEE Trans. Microw. Theory Tech. 52(8), 1987-1991 (2004).
65. Didychuk CL, Ephrat P, Chamson-Reig A et al. Depth of photothermal conversion of gold nanorods embedded in a tissue-like phantom. Nanotechnology 20(19), 195102 (2009).
66. Oleson JR, Robertson E. Hyperthermia from the clinic to the laboratory: A hypothesis. Int. J. Hyperthermia 11(3), 315-322 (1995).
67. Burd R, Dziedzic TS, Xu Y et al. Tumor cell apoptosis, lymphocyte recruitment and tumor vascular changes are induced by low temperature, long duration (fever-like) whole body hyperthermia. J. Cell. Physiol. 177(1), 137-147 (1998).
68. Griffin RJ, Dings RP, Jamshidi-Parsian A et al. Mild temperature hyperthermia and radiation therapy: Role of tumor vascular thermotolerance and relevant physiological factors. Int. J. Hyperthermia 26(3), 256-263 (2010).
69. Jordan A, Scholz R, Wust P et al. Magnetic fluid hyperthermia (MFH): Cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles. J. Magn. Magn. Mater. 201, 413-419 (1999).
70. Maier-Hauff K, Ulrich F, Nestler D et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J. Neurooncol. 103(2), 317-324 (2011).